Anti-pseudomonas aeruginosa immune globulin

Drug Profile

Anti-pseudomonas aeruginosa immune globulin

Alternative Names: Anti-pseudomonas aeruginosa gamma-globulin; Anti-pseudomonas aeruginosa IgY; Anti-Pseudomonas aeruginosa immunoglobulin Y; Anti-pseudomonas IgY; IgY; Pseudomonas aeruginosa immune globulin

Latest Information Update: 22 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator IMMUNSYSTEM
  • Class Antibacterials; Immunotherapies; Polyclonal antibodies
  • Mechanism of Action Cell movement inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 21 Sep 2015 Phase-I/II development for Cystic fibrosis-associated respiratory tract infections (Prevention) is ongoing in Sweden (NCT00633191)
  • 01 Dec 2012 IMMUNSYSTEM completes its phase I/II trial for Cystic fibrosis-associated respiratory tract infections (Prevention) in Sweden (NCT00633191)
  • 23 Mar 2012 IMMUNSYSTEM completes enrolment in its phase I/II trial for Cystic fibrosis-associated respiratory tract infections (Prevention) in Sweden (NCT00633191)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top